Transcatheter aortic valve implantation (TAVI) is the primary therapeutic option for severe aortic stenosis that are inoperable or have high surgical risk. Diffusion-weighted MRI studies demonstrates that after TAVI some silent embolic cerebral infarcts are present that lead to consecutive mental deterioration. Embolic protection devices are used to provide a mechanical barrier against the debris that cause embolization in the brain during TAVI. These devices have reduced the risk of cerebrovascular incidences related to TAVI.

Increase in prevalence of cardiovascular diseases, rise in geriatric population, adoption of advanced surgical techniques, and growth in health care investments drive the market growth. However, high cost of devices and procedure is expected to hinder the growth of the market. In addition, technological advancements leading to development of advanced embolic protection device for TAVI such as CLEAN-TAVI provides various opportunities for the market growth.

The global cerebral embolic protection devices for TAVI market is segmented on the basis of products, application, and geography. According to products, the market is divided into Clarets sentinel system, Keystone Hearts Triguard device, and Embrella embolic deflector. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key players profiled in the report include Keystone Heart, Claret Medical, Inc., and Edwards Lifesciences Corporation.

Key Benefits

• The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
• It presents a quantitative analysis to enable stakeholders to capitalize on the prevailing market opportunities.
• Extensive analysis of the market by country assists in understanding the regional trends.
• Key players and their strategies are analyzed to understand the competitive outlook of the market.

 Key Market Segments

• By Products
  • Clarets Sentinel System
  • Keystone Hearts Triguard Device
  • Embrella Embolic Deflector
• By Region
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

 
Key Market Players

• Contego Medical
• Allium Medica
• Edwards Lifesciences Corporation
• Boston Scientific
• Medtronic
• Abbott Laboratories
• Cardinal Health
• Keystone Heart
• Claret Medical, Inc.
• Gore Medical

• CHAPTER 1: INTRODUCTION

  • 1.1. Report Description

  • 1.2. Key Market Segments

  • 1.3. Key Benefits

  • 1.4. Research Methodology

    • 1.4.1. Primary Research

    • 1.4.2. Secondary Research

    • 1.4.3. Analyst Tools and Models

• CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

• CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope

  • 3.2. Key Findings

    • 3.2.1. Top Investment Pockets

    • 3.2.2. Top Winning Strategies

  • 3.3. Porter's Five Forces Analysis

    • 3.3.1. Bargaining Power of Suppliers

    • 3.3.2. Threat of New Entrants

    • 3.3.3. Threat of Substitutes

    • 3.3.4. Competitive Rivalry

    • 3.3.5. Bargaining Power among Buyers

  • 3.5. Market Dynamics

    • 3.5.1. Drivers

    • 3.5.2. Restraints

    • 3.5.3. Opportunities

• CHAPTER 4: CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI MARKET, BY PRODUCTS

  • 4.1. Market Overview

    • 4.1.1 Market Size and Forecast, By Products

  • 4.2. Clarets Sentinel System

    • 4.2.1. Key Market Trends, Growth Factors and Opportunities

    • 4.2.2. Market Size and Forecast, By Region

    • 4.2.3. Market Share Analysis, By Country

  • 4.3. Keystone Hearts Triguard Device

    • 4.3.1. Key Market Trends, Growth Factors and Opportunities

    • 4.3.2. Market Size and Forecast, By Region

    • 4.3.3. Market Share Analysis, By Country

  • 4.4. Embrella Embolic Deflector

    • 4.4.1. Key Market Trends, Growth Factors and Opportunities

    • 4.4.2. Market Size and Forecast, By Region

    • 4.4.3. Market Share Analysis, By Country

• CHAPTER 5: CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI MARKET, BY REGION

  • 5.1. Market Overview

    • 5.1.1 Market Size and Forecast, By Region

  • 5.2. North America

    • 5.2.1. Key Market Trends and Opportunities

    • 5.2.2. Market Size and Forecast, By Products

    • 5.2.3. Market Size and Forecast, By Country

    • 5.2.4. U.S. Cerebral Embolic Protection Devices For Tavi Market

      • 5.2.4.1. Market Size and Forecast, By Products

    • 5.2.5. Canada Cerebral Embolic Protection Devices For Tavi Market

      • 5.2.5.1. Market Size and Forecast, By Products

    • 5.2.6. Mexico Cerebral Embolic Protection Devices For Tavi Market

      • 5.2.6.1. Market Size and Forecast, By Products

  • 5.3. Europe

    • 5.3.1. Key Market Trends and Opportunities

    • 5.3.2. Market Size and Forecast, By Products

    • 5.3.3. Market Size and Forecast, By Country

    • 5.3.4. France Cerebral Embolic Protection Devices For Tavi Market

      • 5.3.4.1. Market Size and Forecast, By Products

    • 5.3.5. Germany Cerebral Embolic Protection Devices For Tavi Market

      • 5.3.5.1. Market Size and Forecast, By Products

    • 5.3.6. Italy Cerebral Embolic Protection Devices For Tavi Market

      • 5.3.6.1. Market Size and Forecast, By Products

    • 5.3.7. Spain Cerebral Embolic Protection Devices For Tavi Market

      • 5.3.7.1. Market Size and Forecast, By Products

    • 5.3.8. UK Cerebral Embolic Protection Devices For Tavi Market

      • 5.3.8.1. Market Size and Forecast, By Products

    • 5.3.9. Russia Cerebral Embolic Protection Devices For Tavi Market

      • 5.3.9.1. Market Size and Forecast, By Products

    • 5.3.10. Rest Of Europe Cerebral Embolic Protection Devices For Tavi Market

      • 5.3.10.1. Market Size and Forecast, By Products

  • 5.4. Asia-Pacific

    • 5.4.1. Key Market Trends and Opportunities

    • 5.4.2. Market Size and Forecast, By Products

    • 5.4.3. Market Size and Forecast, By Country

    • 5.4.4. China Cerebral Embolic Protection Devices For Tavi Market

      • 5.4.4.1. Market Size and Forecast, By Products

    • 5.4.5. Japan Cerebral Embolic Protection Devices For Tavi Market

      • 5.4.5.1. Market Size and Forecast, By Products

    • 5.4.6. India Cerebral Embolic Protection Devices For Tavi Market

      • 5.4.6.1. Market Size and Forecast, By Products

    • 5.4.7. South Korea Cerebral Embolic Protection Devices For Tavi Market

      • 5.4.7.1. Market Size and Forecast, By Products

    • 5.4.8. Australia Cerebral Embolic Protection Devices For Tavi Market

      • 5.4.8.1. Market Size and Forecast, By Products

    • 5.4.9. Thailand Cerebral Embolic Protection Devices For Tavi Market

      • 5.4.9.1. Market Size and Forecast, By Products

    • 5.4.10. Malaysia Cerebral Embolic Protection Devices For Tavi Market

      • 5.4.10.1. Market Size and Forecast, By Products

    • 5.4.11. Indonesia Cerebral Embolic Protection Devices For Tavi Market

      • 5.4.11.1. Market Size and Forecast, By Products

    • 5.4.12. Rest of Asia Pacific Cerebral Embolic Protection Devices For Tavi Market

      • 5.4.12.1. Market Size and Forecast, By Products

  • 5.5. LAMEA

    • 5.5.1. Key Market Trends and Opportunities

    • 5.5.2. Market Size and Forecast, By Products

    • 5.5.3. Market Size and Forecast, By Country

    • 5.5.4. Brazil Cerebral Embolic Protection Devices For Tavi Market

      • 5.5.4.1. Market Size and Forecast, By Products

    • 5.5.5. South Africa Cerebral Embolic Protection Devices For Tavi Market

      • 5.5.5.1. Market Size and Forecast, By Products

    • 5.5.6. Saudi Arabia Cerebral Embolic Protection Devices For Tavi Market

      • 5.5.6.1. Market Size and Forecast, By Products

    • 5.5.7. UAE Cerebral Embolic Protection Devices For Tavi Market

      • 5.5.7.1. Market Size and Forecast, By Products

    • 5.5.8. Argentina Cerebral Embolic Protection Devices For Tavi Market

      • 5.5.8.1. Market Size and Forecast, By Products

    • 5.5.9. Rest of LAMEA Cerebral Embolic Protection Devices For Tavi Market

      • 5.5.9.1. Market Size and Forecast, By Products

• CHAPTER 6: COMPETITIVE LANDSCAPE

  • 6.1. Introduction

  • 6.2. Top Winning Strategies

  • 6.3. Product Mapping Of Top 10 Player

  • 6.4. Competitive Dashboard

  • 6.5. Competitive Heatmap

  • 6.6. Top Player Positioning, 2024

• CHAPTER 7: COMPANY PROFILES

  • 7.1. Keystone Heart

    • 7.1.1. Company Overview

    • 7.1.2. Key Executives

    • 7.1.3. Company Snapshot

    • 7.1.4. Operating Business Segments

    • 7.1.5. Product Portfolio

    • 7.1.6. Business Performance

    • 7.1.7. Key Strategic Moves and Developments

  • 7.2. Claret Medical, Inc.

    • 7.2.1. Company Overview

    • 7.2.2. Key Executives

    • 7.2.3. Company Snapshot

    • 7.2.4. Operating Business Segments

    • 7.2.5. Product Portfolio

    • 7.2.6. Business Performance

    • 7.2.7. Key Strategic Moves and Developments

  • 7.3. Edwards Lifesciences Corporation

    • 7.3.1. Company Overview

    • 7.3.2. Key Executives

    • 7.3.3. Company Snapshot

    • 7.3.4. Operating Business Segments

    • 7.3.5. Product Portfolio

    • 7.3.6. Business Performance

    • 7.3.7. Key Strategic Moves and Developments

  • 7.4. Abbott Laboratories

    • 7.4.1. Company Overview

    • 7.4.2. Key Executives

    • 7.4.3. Company Snapshot

    • 7.4.4. Operating Business Segments

    • 7.4.5. Product Portfolio

    • 7.4.6. Business Performance

    • 7.4.7. Key Strategic Moves and Developments

  • 7.5. Allium Medica

    • 7.5.1. Company Overview

    • 7.5.2. Key Executives

    • 7.5.3. Company Snapshot

    • 7.5.4. Operating Business Segments

    • 7.5.5. Product Portfolio

    • 7.5.6. Business Performance

    • 7.5.7. Key Strategic Moves and Developments

  • 7.6. Boston Scientific

    • 7.6.1. Company Overview

    • 7.6.2. Key Executives

    • 7.6.3. Company Snapshot

    • 7.6.4. Operating Business Segments

    • 7.6.5. Product Portfolio

    • 7.6.6. Business Performance

    • 7.6.7. Key Strategic Moves and Developments

  • 7.7. Cardinal Health

    • 7.7.1. Company Overview

    • 7.7.2. Key Executives

    • 7.7.3. Company Snapshot

    • 7.7.4. Operating Business Segments

    • 7.7.5. Product Portfolio

    • 7.7.6. Business Performance

    • 7.7.7. Key Strategic Moves and Developments

  • 7.8. Contego Medical

    • 7.8.1. Company Overview

    • 7.8.2. Key Executives

    • 7.8.3. Company Snapshot

    • 7.8.4. Operating Business Segments

    • 7.8.5. Product Portfolio

    • 7.8.6. Business Performance

    • 7.8.7. Key Strategic Moves and Developments

  • 7.9. Gore Medical

    • 7.9.1. Company Overview

    • 7.9.2. Key Executives

    • 7.9.3. Company Snapshot

    • 7.9.4. Operating Business Segments

    • 7.9.5. Product Portfolio

    • 7.9.6. Business Performance

    • 7.9.7. Key Strategic Moves and Developments

  • 7.10. Medtronic

    • 7.10.1. Company Overview

    • 7.10.2. Key Executives

    • 7.10.3. Company Snapshot

    • 7.10.4. Operating Business Segments

    • 7.10.5. Product Portfolio

    • 7.10.6. Business Performance

    • 7.10.7. Key Strategic Moves and Developments

• LIST OF TABLES

• TABLE 1. GLOBAL CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI MARKET, BY PRODUCTS, 2025-2033 ($MILLION)
• TABLE 2. GLOBAL CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI MARKET FOR CLARETS SENTINEL SYSTEM, BY REGION, 2025-2033 ($MILLION)
• TABLE 3. GLOBAL CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI MARKET FOR KEYSTONE HEARTS TRIGUARD DEVICE, BY REGION, 2025-2033 ($MILLION)
• TABLE 4. GLOBAL CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI MARKET FOR EMBRELLA EMBOLIC DEFLECTOR, BY REGION, 2025-2033 ($MILLION)
• TABLE 5. GLOBAL CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI MARKET, BY REGION, 2025-2033 ($MILLION)
• TABLE 6. NORTH AMERICA CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY REGION, 2025-2033 ($MILLION)
• TABLE 7. NORTH AMERICA CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY PRODUCTS, 2025-2033 ($MILLION)
• TABLE 8. U.S. CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY PRODUCTS, 2025-2033 ($MILLION)
• TABLE 9. CANADA CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY PRODUCTS, 2025-2033 ($MILLION)
• TABLE 10. MEXICO CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY PRODUCTS, 2025-2033 ($MILLION)
• TABLE 11. EUROPE CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY REGION, 2025-2033 ($MILLION)
• TABLE 12. EUROPE CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY PRODUCTS, 2025-2033 ($MILLION)
• TABLE 13. FRANCE CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY PRODUCTS, 2025-2033 ($MILLION)
• TABLE 14. GERMANY CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY PRODUCTS, 2025-2033 ($MILLION)
• TABLE 15. ITALY CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY PRODUCTS, 2025-2033 ($MILLION)
• TABLE 16. SPAIN CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY PRODUCTS, 2025-2033 ($MILLION)
• TABLE 17. UK CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY PRODUCTS, 2025-2033 ($MILLION)
• TABLE 18. RUSSIA CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY PRODUCTS, 2025-2033 ($MILLION)
• TABLE 19. REST OF EUROPE CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY PRODUCTS, 2025-2033 ($MILLION)
• TABLE 20. ASIA-PACIFIC CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY REGION, 2025-2033 ($MILLION)
• TABLE 21. ASIA-PACIFIC CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY PRODUCTS, 2025-2033 ($MILLION)
• TABLE 22. CHINA CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY PRODUCTS, 2025-2033 ($MILLION)
• TABLE 23. JAPAN CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY PRODUCTS, 2025-2033 ($MILLION)
• TABLE 24. INDIA CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY PRODUCTS, 2025-2033 ($MILLION)
• TABLE 25. SOUTH KOREA CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY PRODUCTS, 2025-2033 ($MILLION)
• TABLE 26. AUSTRALIA CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY PRODUCTS, 2025-2033 ($MILLION)
• TABLE 27. THAILAND CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY PRODUCTS, 2025-2033 ($MILLION)
• TABLE 28. MALAYSIA CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY PRODUCTS, 2025-2033 ($MILLION)
• TABLE 29. INDONESIA CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY PRODUCTS, 2025-2033 ($MILLION)
• TABLE 30. REST OF ASIA PACIFIC CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY PRODUCTS, 2025-2033 ($MILLION)
• TABLE 31. LAMEA CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY REGION, 2025-2033 ($MILLION)
• TABLE 32. LAMEA CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY PRODUCTS, 2025-2033 ($MILLION)
• TABLE 33. BRAZIL CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY PRODUCTS, 2025-2033 ($MILLION)
• TABLE 34. SOUTH AFRICA CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY PRODUCTS, 2025-2033 ($MILLION)
• TABLE 35. SAUDI ARABIA CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY PRODUCTS, 2025-2033 ($MILLION)
• TABLE 36. UAE CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY PRODUCTS, 2025-2033 ($MILLION)
• TABLE 37. ARGENTINA CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY PRODUCTS, 2025-2033 ($MILLION)
• TABLE 38. REST OF LAMEA CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI, BY PRODUCTS, 2025-2033 ($MILLION)
• TABLE 39. KEYSTONE HEART: KEY EXECUTIVES
• TABLE 40. KEYSTONE HEART: COMPANY SNAPSHOT
• TABLE 41. KEYSTONE HEART: OPERATING SEGMENTS
• TABLE 42. KEYSTONE HEART: PRODUCT PORTFOLIO
• TABLE 43. KEYSTONE HEART: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 44. CLARET MEDICAL, INC.: KEY EXECUTIVES
• TABLE 45. CLARET MEDICAL, INC.: COMPANY SNAPSHOT
• TABLE 46. CLARET MEDICAL, INC.: OPERATING SEGMENTS
• TABLE 47. CLARET MEDICAL, INC.: PRODUCT PORTFOLIO
• TABLE 48. CLARET MEDICAL, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 49. EDWARDS LIFESCIENCES CORPORATION: KEY EXECUTIVES
• TABLE 50. EDWARDS LIFESCIENCES CORPORATION: COMPANY SNAPSHOT
• TABLE 51. EDWARDS LIFESCIENCES CORPORATION: OPERATING SEGMENTS
• TABLE 52. EDWARDS LIFESCIENCES CORPORATION: PRODUCT PORTFOLIO
• TABLE 53. EDWARDS LIFESCIENCES CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 54. ABBOTT LABORATORIES: KEY EXECUTIVES
• TABLE 55. ABBOTT LABORATORIES: COMPANY SNAPSHOT
• TABLE 56. ABBOTT LABORATORIES: OPERATING SEGMENTS
• TABLE 57. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
• TABLE 58. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 59. ALLIUM MEDICA: KEY EXECUTIVES
• TABLE 60. ALLIUM MEDICA: COMPANY SNAPSHOT
• TABLE 61. ALLIUM MEDICA: OPERATING SEGMENTS
• TABLE 62. ALLIUM MEDICA: PRODUCT PORTFOLIO
• TABLE 63. ALLIUM MEDICA: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 64. BOSTON SCIENTIFIC: KEY EXECUTIVES
• TABLE 65. BOSTON SCIENTIFIC: COMPANY SNAPSHOT
• TABLE 66. BOSTON SCIENTIFIC: OPERATING SEGMENTS
• TABLE 67. BOSTON SCIENTIFIC: PRODUCT PORTFOLIO
• TABLE 68. BOSTON SCIENTIFIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 69. CARDINAL HEALTH: KEY EXECUTIVES
• TABLE 70. CARDINAL HEALTH: COMPANY SNAPSHOT
• TABLE 71. CARDINAL HEALTH: OPERATING SEGMENTS
• TABLE 72. CARDINAL HEALTH: PRODUCT PORTFOLIO
• TABLE 73. CARDINAL HEALTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 74. CONTEGO MEDICAL: KEY EXECUTIVES
• TABLE 75. CONTEGO MEDICAL: COMPANY SNAPSHOT
• TABLE 76. CONTEGO MEDICAL: OPERATING SEGMENTS
• TABLE 77. CONTEGO MEDICAL: PRODUCT PORTFOLIO
• TABLE 78. CONTEGO MEDICAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 79. GORE MEDICAL: KEY EXECUTIVES
• TABLE 80. GORE MEDICAL: COMPANY SNAPSHOT
• TABLE 81. GORE MEDICAL: OPERATING SEGMENTS
• TABLE 82. GORE MEDICAL: PRODUCT PORTFOLIO
• TABLE 83. GORE MEDICAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 84. MEDTRONIC: KEY EXECUTIVES
• TABLE 85. MEDTRONIC: COMPANY SNAPSHOT
• TABLE 86. MEDTRONIC: OPERATING SEGMENTS
• TABLE 87. MEDTRONIC: PRODUCT PORTFOLIO
• TABLE 88. MEDTRONIC: KEY STRATEGIC MOVES AND DEVELOPMENTS

• LIST OF FIGURES

• FIGURE 1. GLOBAL CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI MARKET SEGMENTATION
• FIGURE 2. GLOBAL CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI MARKET
• FIGURE 3. SEGMENTATION CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI MARKET
• FIGURE 4. TOP INVESTMENT POCKET IN CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI MARKET
• FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
• FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
• FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
• FIGURE 8. LOW THREAT OF SUBSTITUTION
• FIGURE 9. HIGH COMPETITIVE RIVALRY
• FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALCEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI MARKET
• FIGURE 11. CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI MARKET SEGMENTATION, BY BY PRODUCTS
• FIGURE 12. CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI MARKET FOR CLARETS SENTINEL SYSTEM, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 13. CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI MARKET FOR KEYSTONE HEARTS TRIGUARD DEVICE, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 14. CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI MARKET FOR EMBRELLA EMBOLIC DEFLECTOR, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 15. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
• FIGURE 16. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
• FIGURE 17. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
• FIGURE 18. PRODUCT MAPPING OF TOP 10 PLAYERS
• FIGURE 19. COMPETITIVE DASHBOARD
• FIGURE 20. COMPETITIVE HEATMAP: CEREBRAL EMBOLIC PROTECTION DEVICES FOR TAVI MARKET
• FIGURE 21. TOP PLAYER POSITIONING, 2024
• FIGURE 22. KEYSTONE HEART: NET SALES, 2022-2024 ($MILLION)
• FIGURE 23. KEYSTONE HEART: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 24. KEYSTONE HEART: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 25. CLARET MEDICAL, INC.: NET SALES, 2022-2024 ($MILLION)
• FIGURE 26. CLARET MEDICAL, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 27. CLARET MEDICAL, INC.: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 28. EDWARDS LIFESCIENCES CORPORATION: NET SALES, 2022-2024 ($MILLION)
• FIGURE 29. EDWARDS LIFESCIENCES CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 30. EDWARDS LIFESCIENCES CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 31. ABBOTT LABORATORIES: NET SALES, 2022-2024 ($MILLION)
• FIGURE 32. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 33. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 34. ALLIUM MEDICA: NET SALES, 2022-2024 ($MILLION)
• FIGURE 35. ALLIUM MEDICA: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 36. ALLIUM MEDICA: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 37. BOSTON SCIENTIFIC: NET SALES, 2022-2024 ($MILLION)
• FIGURE 38. BOSTON SCIENTIFIC: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 39. BOSTON SCIENTIFIC: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 40. CARDINAL HEALTH: NET SALES, 2022-2024 ($MILLION)
• FIGURE 41. CARDINAL HEALTH: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 42. CARDINAL HEALTH: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 43. CONTEGO MEDICAL: NET SALES, 2022-2024 ($MILLION)
• FIGURE 44. CONTEGO MEDICAL: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 45. CONTEGO MEDICAL: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 46. GORE MEDICAL: NET SALES, 2022-2024 ($MILLION)
• FIGURE 47. GORE MEDICAL: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 48. GORE MEDICAL: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 49. MEDTRONIC: NET SALES, 2022-2024 ($MILLION)
• FIGURE 50. MEDTRONIC: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 51. MEDTRONIC: REVENUE SHARE, BY REGION, 2024 (%)